---
title: "RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286254871.md"
description: "RBC Capital analyst Brian Abrahams has maintained a Hold rating on Lakefront Biotherapeutics (LKFT) with a price target of $28.00. Abrahams, a 5-star analyst, has an average return of 10.1% and a 51.10% success rate. The overall analyst consensus for Lakefront Biotherapeutics is a Moderate Sell, with an average price target of $25.00."
datetime: "2026-05-13T11:47:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286254871.md)
  - [en](https://longbridge.com/en/news/286254871.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286254871.md)
---

# RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Lakefront Biotherapeutics today and set a price target of $28.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Abrahams is a 5-star analyst with an average return of 10.1% and a 51.10% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, ACADIA Pharmaceuticals, and BioCryst.

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Lakefront Biotherapeutics with a $25.00 average price target.

### Related Stocks

- [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)](https://longbridge.com/en/news/285789492.md)
- [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md)
- [Earnings Beat: Odfjell Drilling Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286515920.md)
- [Linde plc Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/286077553.md)